Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced that CEO Gaurav Shah will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:50 p.m. ET. The presentation will focus on the company's clinical-stage pipeline of genetic therapies targeting rare childhood disorders, including Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and others. A live audio webcast will be available on Rocket's investor website, with a replay accessible post-conference.

Positive

• CEO Gaurav Shah scheduled to present at a major healthcare conference, indicating proactive engagement with investors.
• Focus on advancing an integrated pipeline of genetic therapies for rare childhood disorders, reflecting strong developmental efforts.

Negative

• None.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is scheduled to present on Monday, January 11, 2021, at 2:50 p.m. Eastern Time at the 39^th Annual J.P. Morgan Healthcare Conference.

A live audio webcast of the presentation will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.

About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005283/en/

FAQ

When is Rocket Pharmaceuticals presenting at the J.P. Morgan Healthcare Conference?

Rocket Pharmaceuticals will present on January 11, 2021, at 2:50 p.m. ET.

What is the focus of Rocket Pharmaceuticals' presentation at the conference?

The presentation will discuss the company's pipeline of genetic therapies for rare childhood disorders.

Where can I watch Rocket Pharmaceuticals' presentation?

A live audio webcast will be available on the Investors section of Rocket Pharmaceuticals' website.

What diseases are included in Rocket Pharmaceuticals' clinical programs?

The clinical programs target Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and others.